Candel Therapeutics Inc (NASDAQ:CADL) has a beta value of -0.96 and has seen 8.05 million shares traded in the last trading session. The company, currently valued at $137.68M, closed the last trade at $6.16 per share which meant it lost -$0.59 on the day or -8.81% during that session. The CADL stock price is -137.01% off its 52-week high price of $14.60 and 83.44% above the 52-week low of $1.02. If we look at the company’s 10-day average daily trading volume, we find that it stood at 15.41 million shares traded. The 3-month trading volume is 2.71 million shares.
The consensus among analysts is that Candel Therapeutics Inc (CADL) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Sporting -8.81% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CADL stock price touched $6.16 or saw a rise of 57.81%. Year-to-date, Candel Therapeutics Inc shares have moved 318.71%, while the 5-day performance has seen it change 21.88%. Over the past 30 days, the shares of Candel Therapeutics Inc (NASDAQ:CADL) have changed 43.14%. Short interest in the company has seen 1.78 million shares shorted with days to cover at 7.72.
Candel Therapeutics Inc (CADL) estimates and forecasts
Figures show that Candel Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -14.75% over the past 6 months, with this year growth rate of -25.95%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -46.75% over the past 5 years.
CADL Dividends
Candel Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
Insiders own 30.39% of the company shares, while shares held by institutions stand at 22.53% with a share float percentage of 32.37%. Investors are also buoyed by the number of investors in a company, with Candel Therapeutics Inc having a total of 74.0 institutions that hold shares in the company. The top two institutional holders are NORTHPOND VENTURES, LLC with over 1.94 million shares worth more than $12.0 million. As of 2024-06-30, NORTHPOND VENTURES, LLC held 6.628% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 0.82 million shares as of 2024-06-30. The firm’s total holdings are worth over $5.1 million and represent 2.819% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 1.59% shares in the company for having 517.36 shares of worth $3.18 million while later fund manager owns 453.81 shares of worth $2.79 million as of Sep 30, 2024 , which makes it owner of about 1.40% of company’s outstanding stock.
